Lindbrook Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
$6.06K Buy
209
+155
+287% +$4.95K ﹤0.01% 1876
2024
Q4
$2K Sell
54
-10
-16% -$457 ﹤0.01% 2304
2024
Q3
$3.11K Buy
64
+10
+19% +$439 ﹤0.01% 2205
2024
Q2
$2.16K Sell
54
-9
-14% -$373 ﹤0.01% 2325
2024
Q1
$2.77K Sell
63
-32
-34% -$1.65K ﹤0.01% 2130
2023
Q4
$5.88K Buy
95
+41
+76% +$2.15K ﹤0.01% 1801
2023
Q3
$2.48K Hold
54
﹤0.01% 2048
2023
Q2
$3.1K Hold
54
﹤0.01% 1990
2023
Q1
$2.02K Buy
54
+12
+29% +$393 ﹤0.01% 2242
2022
Q4
$1.18K Sell
42
-102
-71% -$2.96K ﹤0.01% 2426
2022
Q3
$4K Buy
144
+68
+89% +$2.22K ﹤0.01% 1726
2022
Q2
$3K Sell
76
-29
-28% -$1.03K ﹤0.01% 1736
2022
Q1
$4K Buy
105
+29
+38% +$822 ﹤0.01% 1666
2021
Q4
$2K Buy
76
+34
+81% +$695 ﹤0.01% 1740
2021
Q3
$1K Hold
42
﹤0.01% 1667
2021
Q2
$1K Hold
42
﹤0.01% 1698
2021
Q1
$1K Hold
42
﹤0.01% 1662
2020
Q4
$1K Hold
42
﹤0.01% 1563
2020
Q3
$1K Hold
42
﹤0.01% 1500
2020
Q2
$1K Hold
42
﹤0.01% 1505
2020
Q1
$1K Buy
+42
New +$731 ﹤0.01% 1377

Other funds holding AMPH

Lindbrook Capital's AMPH Position: Q1 2025 in Review

Lindbrook Capital increased its Amphastar Pharmaceuticals (AMPH) stake by 287% in Q1 2025, buying an estimated $4.95K and bringing the position to 209 shares worth $6.06K. The position accounts for ﹤0.01% of the portfolio, ranked #1876.

Lindbrook Capital first reported a position in AMPH in Q1 2020 and has held it in 21 quarters since. 241 funds tracked by Wall St. Rank hold AMPH as of Q1 2025.

  • Lindbrook Capital held 209 shares of Amphastar Pharmaceuticals worth $6.06K as of Q1 2025.
  • Lindbrook Capital bought 155 Amphastar Pharmaceuticals shares in Q1 2025, an estimated $4.95K.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1876 holding.
  • Lindbrook Capital first reported a position in Amphastar Pharmaceuticals in Q1 2020 and has held it in 21 quarters since.
  • 241 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.